- Home
- VRAX vs SCNI Comparison
VRAX vs SCNI Comparison
Compare VRAX & SCNI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | VRAX | SCNI |
|---|---|---|
| Founded | 2013 | 2003 |
| Country | United Kingdom | Israel |
| Employees | N/A | N/A |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5M | 1.2M |
| IPO Year | 2021 | 2014 |
Fundamental Metrics
Financial Performance| Metric | VRAX | SCNI |
|---|---|---|
| Price | $1.24 | $0.61 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 150.3K | ★ 1.1M |
| Earning Date | 11-20-2026 | 08-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 50.00 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.10 | $0.21 |
| 52 Week High | $13.19 | $3.58 |
Technical Indicators
Market Signals| Indicator | VRAX | SCNI |
|---|---|---|
| Relative Strength Index (RSI) | 21.48 | 30.42 |
| Support Level | $0.16 | $0.47 |
| Resistance Level | $3.01 | $1.02 |
| Average True Range (ATR) | 0.29 | 0.15 |
| MACD | -0.05 | -0.06 |
| Stochastic Oscillator | 2.69 | 4.14 |
Price Performance
Historical ComparisonAbout VRAX Virax Biolabs Group Limited
Virax Biolabs Group Ltd is a biotechnology company focused on the detection of immune responses and the development of immune profiling and in vitro diagnostic technologies for viral and immune-mediated diseases, with a current strategic focus on post-acute infection syndromes (PAIS) and related areas of chronic immune dysfunction. The company's principal development activities are centered on T cell-based in vitro diagnostics and immune profiling. The company's flagship product candidate, ViraxImmune, is an in-development T cell-based assay and immune profiling platform intended to support the assessment of immune dysfunction, initially in PAIS indications.
About SCNI Scinai Immunotherapeutics Ltd.
Scinai Immunotherapeutics Ltd is a biopharmaceutical company with two complementary business units: (i) Scinai R&D, focused on the development of therapeutics in inflammation and immunology, and (ii) the contract development and manufacturing organization (CDMO) business. The CDMO business provides integrated development and manufacturing services to small and emerging biotech companies, supporting clients from early-stage development through clinical-stage production.